Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

Giulio Metro, Rita Chiari, Simona Duranti, Annamaria Siggillino, Matthias J. Fischer, Diana Giannarelli, Vienna Ludovini, Chiara Bennati, Luca Marcomigni, Alice Baldi, Michele Giansanti, Vincenzo Minotti, Lucio Crinò

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Introduction: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). Methods: Patients with an EGFR WT genotype who were treated with an EGFR-TKI for advanced disease at our Institution were identified. Simultaneous availability of KRAS mutation status was required for study inclusion. Results: Sixty-seven patients were eligible. Median age was 60 years (39-84), and 10 patients (14.9%) had received an EGFR-TKI as upfront therapy. Overall, the median progression-free survival (PFS) and overall survival (OS) were 2.9 months and 18.0 months, respectively. KRAS mutant patients (n= 18) experienced a significantly shorter PFS compared with those carrying a KRAS WT genotype (n= 49) (1.6 months vs 3.0 months, respectively, P= 0.04; HR = 1.92). However, within the KRAS mutant group a great variability in terms of sensitivity to treatment was noted (PFS ranging from 0.7 months to 38.7 months). KRAS codon 13 mutant patients (n= 4) experienced the worse outcome when compared with KRAS codon 12 mutants (n= 14) and KRAS WT patients (P<0.0001 and P= 0.01 for PFS and OS, respectively). Conclusions: Though we found that EGFR WT/. KRAS mutant advanced NSCLC patients are associated with an increased resistance to treatment, specific mutant KRAS may account for differential sensitivity to an EGFR-TKI. KRAS codon 13 mutants are those who seem to experience the worse clinical outcome.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalLung Cancer
Volume78
Issue number1
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Genotype
Disease-Free Survival
Codon
Survival
Therapeutics
Retrospective Studies
Mutation

Keywords

  • EGFR
  • EGFR-TKI
  • Erlotinib
  • Gefitinib
  • KRAS
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. / Metro, Giulio; Chiari, Rita; Duranti, Simona; Siggillino, Annamaria; Fischer, Matthias J.; Giannarelli, Diana; Ludovini, Vienna; Bennati, Chiara; Marcomigni, Luca; Baldi, Alice; Giansanti, Michele; Minotti, Vincenzo; Crinò, Lucio.

In: Lung Cancer, Vol. 78, No. 1, 10.2012, p. 81-86.

Research output: Contribution to journalArticle

Metro, G, Chiari, R, Duranti, S, Siggillino, A, Fischer, MJ, Giannarelli, D, Ludovini, V, Bennati, C, Marcomigni, L, Baldi, A, Giansanti, M, Minotti, V & Crinò, L 2012, 'Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype', Lung Cancer, vol. 78, no. 1, pp. 81-86. https://doi.org/10.1016/j.lungcan.2012.06.005
Metro, Giulio ; Chiari, Rita ; Duranti, Simona ; Siggillino, Annamaria ; Fischer, Matthias J. ; Giannarelli, Diana ; Ludovini, Vienna ; Bennati, Chiara ; Marcomigni, Luca ; Baldi, Alice ; Giansanti, Michele ; Minotti, Vincenzo ; Crinò, Lucio. / Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. In: Lung Cancer. 2012 ; Vol. 78, No. 1. pp. 81-86.
@article{a87c3caecece4b20a966377e7047a3ac,
title = "Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype",
abstract = "Introduction: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). Methods: Patients with an EGFR WT genotype who were treated with an EGFR-TKI for advanced disease at our Institution were identified. Simultaneous availability of KRAS mutation status was required for study inclusion. Results: Sixty-seven patients were eligible. Median age was 60 years (39-84), and 10 patients (14.9{\%}) had received an EGFR-TKI as upfront therapy. Overall, the median progression-free survival (PFS) and overall survival (OS) were 2.9 months and 18.0 months, respectively. KRAS mutant patients (n= 18) experienced a significantly shorter PFS compared with those carrying a KRAS WT genotype (n= 49) (1.6 months vs 3.0 months, respectively, P= 0.04; HR = 1.92). However, within the KRAS mutant group a great variability in terms of sensitivity to treatment was noted (PFS ranging from 0.7 months to 38.7 months). KRAS codon 13 mutant patients (n= 4) experienced the worse outcome when compared with KRAS codon 12 mutants (n= 14) and KRAS WT patients (P<0.0001 and P= 0.01 for PFS and OS, respectively). Conclusions: Though we found that EGFR WT/. KRAS mutant advanced NSCLC patients are associated with an increased resistance to treatment, specific mutant KRAS may account for differential sensitivity to an EGFR-TKI. KRAS codon 13 mutants are those who seem to experience the worse clinical outcome.",
keywords = "EGFR, EGFR-TKI, Erlotinib, Gefitinib, KRAS, Non-small cell lung cancer",
author = "Giulio Metro and Rita Chiari and Simona Duranti and Annamaria Siggillino and Fischer, {Matthias J.} and Diana Giannarelli and Vienna Ludovini and Chiara Bennati and Luca Marcomigni and Alice Baldi and Michele Giansanti and Vincenzo Minotti and Lucio Crin{\`o}",
year = "2012",
month = "10",
doi = "10.1016/j.lungcan.2012.06.005",
language = "English",
volume = "78",
pages = "81--86",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

AU - Metro, Giulio

AU - Chiari, Rita

AU - Duranti, Simona

AU - Siggillino, Annamaria

AU - Fischer, Matthias J.

AU - Giannarelli, Diana

AU - Ludovini, Vienna

AU - Bennati, Chiara

AU - Marcomigni, Luca

AU - Baldi, Alice

AU - Giansanti, Michele

AU - Minotti, Vincenzo

AU - Crinò, Lucio

PY - 2012/10

Y1 - 2012/10

N2 - Introduction: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). Methods: Patients with an EGFR WT genotype who were treated with an EGFR-TKI for advanced disease at our Institution were identified. Simultaneous availability of KRAS mutation status was required for study inclusion. Results: Sixty-seven patients were eligible. Median age was 60 years (39-84), and 10 patients (14.9%) had received an EGFR-TKI as upfront therapy. Overall, the median progression-free survival (PFS) and overall survival (OS) were 2.9 months and 18.0 months, respectively. KRAS mutant patients (n= 18) experienced a significantly shorter PFS compared with those carrying a KRAS WT genotype (n= 49) (1.6 months vs 3.0 months, respectively, P= 0.04; HR = 1.92). However, within the KRAS mutant group a great variability in terms of sensitivity to treatment was noted (PFS ranging from 0.7 months to 38.7 months). KRAS codon 13 mutant patients (n= 4) experienced the worse outcome when compared with KRAS codon 12 mutants (n= 14) and KRAS WT patients (P<0.0001 and P= 0.01 for PFS and OS, respectively). Conclusions: Though we found that EGFR WT/. KRAS mutant advanced NSCLC patients are associated with an increased resistance to treatment, specific mutant KRAS may account for differential sensitivity to an EGFR-TKI. KRAS codon 13 mutants are those who seem to experience the worse clinical outcome.

AB - Introduction: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). Methods: Patients with an EGFR WT genotype who were treated with an EGFR-TKI for advanced disease at our Institution were identified. Simultaneous availability of KRAS mutation status was required for study inclusion. Results: Sixty-seven patients were eligible. Median age was 60 years (39-84), and 10 patients (14.9%) had received an EGFR-TKI as upfront therapy. Overall, the median progression-free survival (PFS) and overall survival (OS) were 2.9 months and 18.0 months, respectively. KRAS mutant patients (n= 18) experienced a significantly shorter PFS compared with those carrying a KRAS WT genotype (n= 49) (1.6 months vs 3.0 months, respectively, P= 0.04; HR = 1.92). However, within the KRAS mutant group a great variability in terms of sensitivity to treatment was noted (PFS ranging from 0.7 months to 38.7 months). KRAS codon 13 mutant patients (n= 4) experienced the worse outcome when compared with KRAS codon 12 mutants (n= 14) and KRAS WT patients (P<0.0001 and P= 0.01 for PFS and OS, respectively). Conclusions: Though we found that EGFR WT/. KRAS mutant advanced NSCLC patients are associated with an increased resistance to treatment, specific mutant KRAS may account for differential sensitivity to an EGFR-TKI. KRAS codon 13 mutants are those who seem to experience the worse clinical outcome.

KW - EGFR

KW - EGFR-TKI

KW - Erlotinib

KW - Gefitinib

KW - KRAS

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84866147012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866147012&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2012.06.005

DO - 10.1016/j.lungcan.2012.06.005

M3 - Article

C2 - 22770374

AN - SCOPUS:84866147012

VL - 78

SP - 81

EP - 86

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -